Employees at bluebird bio rank Nick Leschly in the Bottom 5% of CEOs in Boston. Comparatively, employees at BlueRock Therapeutics rank SETH ETTENBERG, PH.D. in the Top 5% of CEOs in Boston. Employees rate their CEO differently based on the frequency of interaction, ability to affect company culture, and drive measurable results.

Nick Leschly

CEO of bluebird bio

BIO: Mr. Nick Leschly has been the Chief Executive Officer and President at bluebird bio, Inc. (alternate name Genetix Pharmaceuticals Inc.) since September 2010. Mr. Leschly served as Interim President at bluebird bio, Inc. until September 2010. He was a Partner at Third Rock Ventures, LLC since 2007. He served as the Chief Business Officer of Agios Pharmaceuticals, Inc. Prior to joining Third Rock, he was the Product and Alliance Leader for Millennium Pharmaceuticals, Inc., and was the Product Leader for VELCADE???, managing a S100M+ global development plan. Mr. Leschly founded and served as the Chief Financial Officer of MedXtend Corporation. He joined Third Rock Ventures in 2007 as a Founding Member and played an integral role in the overall formation, development and business strategy of several of Third Rock's portfolio companies, including Agios Pharmaceuticals (AGIO), Inc. as well as identifying and evaluating new investments. He worked at Accenture Consulting, where he focused on the pharmaceutical industry. Mr. Leschly has been a Director of bluebird bio, Inc. since March 2010. He has been an Independent Director at Synlogic, Inc. since March 2016. Mr. Leschly served as Director of Edimer Pharmaceuticals Inc. He is the Founder and Chairman of The CAVU foundation. He is a Board Member of the Biotechnology Innovation Organization (BIO). Mr. Leschly holds a BS in Molecular Biology from Princeton University and an MBA from Wharton Business School.

SETH ETTENBERG, PH.D.

CEO of BlueRock Therapeutics

BIO: Seth Ettenberg, PhD, is the current President and CEO of BlueRock Therapeutics. Seth served as Chief Scientific Officer at BlueRock from 2020 - 2021. Prior to joining BlueRock, Seth was a founding member of the Unum Therapeutics team, where he served as Chief Scientific Officer. Previously, Seth headed the Cambridge Site of Novartis’ Oncology Biotherapeutics, leading strategy, innovation, and implementation of drug development projects of Novartis Institutes for Biomedical Research (NIBR). In addition, Seth was responsible for building and leading the Novartis Cell and Gene Therapy research team in collaboration with the University of Pennsylvania to develop chimeric antigen receptor T-cell therapeutics. Seth received his formal scientific training at the Genetics Branch of the National Cancer Institute.